Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
about
Opposite effect of NF-kB and c-Jun N-terminal kinase on p53-independent GADD45 induction by arseniteArsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemiaIntracellular calcium disturbances induced by arsenic and its methylated derivatives in relation to genomic damage and apoptosis induction.Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsArsenic inhibition of telomerase transcription leads to genetic instabilityArsenic exposure predicts bladder cancer survival in a US populationNitric oxide and calcium ions in apoptotic esophageal carcinoma cells induced by arsenite.A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosisArsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway.Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway.Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells.Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.Autophagy is the predominant process induced by arsenite in human lymphoblastoid cell linesArsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyArsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growthA family of drug transporters: the multidrug resistance-associated proteins.Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsArsenic trioxide - An old drug rediscovered.Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas.Arsenic trioxide, a therapeutic agent for APL.Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.Induction of Apoptosis in the Rat Bone Marrow Mesenchymal Stem Cells Following Sodium Arsenite Treatment with the Dose Lesser than that Used for Treatment of Malignant Patient.Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.Tetraarsenic Hexoxide Induces Beclin-1-Induced Autophagic Cell Death as well as Caspase-Dependent Apoptosis in U937 Human Leukemic Cells.Current trends in large cell lymphoma.Mitochondria: a target for cancer therapy.Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.Preparation of a nanosized as(2)o(3)/mn(0.5)zn(0.5)fe(2)o(4) complex and its anti-tumor effect on hepatocellular carcinoma cells.Acute promyelocytic leukemia: a model of molecular target based therapy.Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide.The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species.Mitochondrial medicine: pharmacological targeting of mitochondria in diseaseLymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model.Arsenite activates NFκB through induction of C-reactive protein.
P2860
Q23912784-66ACE5C0-A982-4FCA-A270-CEA5183324A2Q24548302-44372D8F-B0FF-4C6D-810E-BBCBE4021CA8Q24813110-9AEBFEBF-8AB2-400E-A280-7F59FE5367BFQ27824789-D6E733E4-A65E-4D39-9B74-244243187898Q28344657-2B5898BE-8CB4-46F6-9996-F3A70CA8E26EQ28364496-D7BC0C0E-AF4B-48B0-B031-4CCDC16D8014Q28397390-57F253EF-A7EC-41FD-8646-2854B9F4C1BAQ30724199-A2613A3D-46D7-4DDF-B37A-09F0708A8AD7Q33203379-12845F85-1A0C-4DA9-9244-16A105A79E41Q33211246-03D163FB-F8EF-4E68-9E93-267BF243EE90Q33218586-CABA5DFE-097D-4F1B-8CFE-62EB1B66E117Q33226642-374E204E-08B6-4F3D-93DC-4E271A58C911Q33665774-F4352626-2B34-4306-A3B1-0BC3FA7EFB1AQ33770808-18FC108A-D50B-44ED-9B6E-F09687A46D07Q33862077-A5D9F980-B343-4879-A24D-E466A2654E0BQ33929824-BC5CD0BD-8689-4EE2-9453-286847BC26C6Q33962155-2C7544BB-5DAE-4829-AF4E-65646B3F84DDQ33976179-3B7AD0E4-BB75-4B8A-97C3-153BF483BC9DQ34004952-2D49012C-9042-488D-A432-6129918F876FQ34020461-0BC7C162-7C01-4B6B-AF1D-22EFB202F869Q34054167-A9E6752C-3770-463F-B99C-660B6AB3801EQ34128180-FBF689D0-92D6-4A9A-ADB8-E73945AEC7D8Q34355231-0800BC73-60CA-44F5-963A-75CD1B19C1F4Q34435492-F6821800-2E13-48AE-9736-30BF121ADB5BQ34591697-F921316D-40DC-4A79-8D3A-9A0DDAAD76E0Q34611982-F955A567-ABC0-4582-A1CF-D3C14E17B9EDQ34620647-B171FC31-7128-4477-93F2-0870103B8FCBQ35186892-127BF4D7-2AB0-4DDC-9F8E-2F6CF4D8D2FBQ35207675-3F730D58-D50B-4330-9FDE-705E21BF9ECBQ35545076-593AE58F-C31A-493F-A792-DE04C6CAE213Q35545214-9352F576-93AE-4E35-9DD1-B60F48957DC7Q35751083-1C2DED11-449A-4943-9D7A-E11C7B9CFD19Q35790392-AE68B59E-543B-4C7C-8730-2251CCA265F4Q36270144-645FB540-014A-4935-B002-937244AF0139Q36309102-4010B35D-AAB6-482F-952E-5AE28E072F9EQ36309105-24FD1570-EECF-425D-9A57-C940DD90C9FAQ36358060-22F74DBB-B0DF-4457-93A5-24C167D753E1Q36453943-B0E74F78-6B0B-4424-BAB1-B6805B8E0F47Q36635049-79CACC2B-1BDE-4B73-BC8B-D3BED98D3F56Q36688397-D914240D-18E2-4DC9-8434-FF6D816575E0
P2860
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Apoptosis and growth inhibitio ...... ally achievable concentrations
@ast
Apoptosis and growth inhibitio ...... ally achievable concentrations
@en
Apoptosis and growth inhibitio ...... ally achievable concentrations
@nl
type
label
Apoptosis and growth inhibitio ...... ally achievable concentrations
@ast
Apoptosis and growth inhibitio ...... ally achievable concentrations
@en
Apoptosis and growth inhibitio ...... ally achievable concentrations
@nl
prefLabel
Apoptosis and growth inhibitio ...... ally achievable concentrations
@ast
Apoptosis and growth inhibitio ...... ally achievable concentrations
@en
Apoptosis and growth inhibitio ...... ally achievable concentrations
@nl
P2093
P2860
P356
P1476
Apoptosis and growth inhibitio ...... ally achievable concentrations
@en
P2093
P2860
P356
10.1093/JNCI/91.9.772
P407
P577
1999-05-05T00:00:00Z